US4634665A
(en)
|
1980-02-25 |
1987-01-06 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
US4399216A
(en)
|
1980-02-25 |
1983-08-16 |
The Trustees Of Columbia University |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
US5179017A
(en)
|
1980-02-25 |
1993-01-12 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
US5156840A
(en)
|
1982-03-09 |
1992-10-20 |
Cytogen Corporation |
Amine-containing porphyrin derivatives
|
US5057313A
(en)
|
1986-02-25 |
1991-10-15 |
The Center For Molecular Medicine And Immunology |
Diagnostic and therapeutic antibody conjugates
|
DE3883899T3
(de)
|
1987-03-18 |
1999-04-22 |
Sb2 Inc |
Geänderte antikörper.
|
IL162181A
(en)
|
1988-12-28 |
2006-04-10 |
Pdl Biopharma Inc |
A method of producing humanized immunoglubulin, and polynucleotides encoding the same
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
JPH0395163A
(ja)
|
1989-09-08 |
1991-04-19 |
Daicel Chem Ind Ltd |
2.2.4.4.6―ペンタメチル―2.3.4.5―テトラヒドロピリミジンの製造法
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
DK0590058T3
(da)
|
1991-06-14 |
2004-03-29 |
Genentech Inc |
Humaniseret heregulin-antistof
|
JPH07501451A
(ja)
|
1991-11-25 |
1995-02-16 |
エンゾン・インコーポレイテッド |
多価抗原結合タンパク質
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
US5827690A
(en)
|
1993-12-20 |
1998-10-27 |
Genzyme Transgenics Corporatiion |
Transgenic production of antibodies in milk
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
DK0859841T3
(da)
|
1995-08-18 |
2002-09-09 |
Morphosys Ag |
Protein/(poly)peptidbiblioteker
|
US20020077461A1
(en)
|
1996-04-24 |
2002-06-20 |
Soren Bjorn |
Pharmaceutical formulation
|
CZ2002934A3
(cs)
|
1999-09-17 |
2002-07-17 |
Abbott Gmbh & Co. Kg |
Inhibitory kinázy jako terapeutická činidla
|
AU1560802A
(en)
|
2000-06-28 |
2002-01-08 |
Smithkline Beecham Plc |
Wet milling process
|
SI1385551T1
(sl)
|
2001-04-06 |
2008-12-31 |
Wyeth Five Giralda Farms |
Antineoplastiäśne kombinacije, ki vsebujejo cci-779 (derivat rapamicina) skupaj z gemcitabinom ali fluorouracilom
|
GB0221697D0
(en)
|
2002-09-18 |
2002-10-30 |
Unilever Plc |
Novel compouds and their uses
|
WO2004035580A1
(en)
|
2002-10-21 |
2004-04-29 |
Aprea Ab |
Reactivation of wild type p53 in human tumour cells by a low molecular weight compound
|
AU2004204494B2
(en)
|
2003-01-09 |
2011-09-29 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
EP1585767A2
(en)
|
2003-01-16 |
2005-10-19 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
US20050008625A1
(en)
|
2003-02-13 |
2005-01-13 |
Kalobios, Inc. |
Antibody affinity engineering by serial epitope-guided complementarity replacement
|
JP4989217B2
(ja)
|
2003-03-26 |
2012-08-01 |
エガレット エイ/エス |
薬剤物質の送達制御用マトリックス組成物
|
DK1639014T3
(da)
|
2003-06-13 |
2011-01-17 |
Biogen Idec Inc |
Aglycosyl-anti-CD154 (CD40-ligand)-antistoffer og anvendelser deraf
|
JP2007503206A
(ja)
|
2003-08-22 |
2007-02-22 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
変更されたエフェクター機能を有する改良された抗体およびその抗体を産生する方法
|
US20050203063A1
(en)
|
2003-09-12 |
2005-09-15 |
Raymond Deshaies |
Proteasome pathway inhibitors and related methods
|
PT1740591E
(pt)
|
2004-04-02 |
2009-09-24 |
Osi Pharm Inc |
Inibidores da proteína quinase heterobicíclicos em substituição de anel bicíclico 6,6
|
UY28931A1
(es)
|
2004-06-03 |
2005-12-30 |
Bayer Pharmaceuticals Corp |
Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
|
TW200613306A
(en)
|
2004-07-20 |
2006-05-01 |
Osi Pharm Inc |
Imidazotriazines as protein kinase inhibitors
|
UY29177A1
(es)
|
2004-10-25 |
2006-05-31 |
Astex Therapeutics Ltd |
Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
|
EP1885352A2
(en)
|
2004-11-24 |
2008-02-13 |
Novartis AG |
Combinations comprising jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors
|
JP5335432B2
(ja)
|
2005-11-17 |
2013-11-06 |
オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー |
縮合2環系mTOR阻害剤
|
KR101461680B1
(ko)
|
2005-12-02 |
2014-11-19 |
바이엘 헬스케어 엘엘씨 |
과다-증식성 장애 및 맥관형성과 관련된 질환의 치료에유용한 치환된 4-아미노-피롤로트리아진 유도체
|
PE20070855A1
(es)
|
2005-12-02 |
2007-10-14 |
Bayer Pharmaceuticals Corp |
Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
|
DK2343299T3
(en)
|
2005-12-13 |
2016-01-18 |
Incyte Holdings Corp |
Heteroberl-substituted pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines as Janus kinase inhibitors
|
US7601713B2
(en)
|
2005-12-15 |
2009-10-13 |
Rigel Pharmaceuticals, Inc. |
Kinase inhibitors and their uses
|
AR060432A1
(es)
|
2006-04-12 |
2008-06-18 |
Vertex Pharma |
Tetrahidropteridinas utiles como inhibidores de las proteinas quinasas
|
LT2010528T
(lt)
|
2006-04-19 |
2017-12-27 |
Novartis Ag |
6-o-pakeistieji benzoksazolo junginiai bei csf-1r signalo perdavimo slopinimo būdai
|
US20090253718A1
(en)
|
2006-04-25 |
2009-10-08 |
Astex Therapeutics Limited |
Pharmaceutical Compounds
|
WO2008048375A1
(en)
|
2006-05-19 |
2008-04-24 |
Bayer Healthcare Ag |
Pyridonecarboxamide derivatives useful in treating hyper-proliferative and angiogenesis disorders
|
US8097630B2
(en)
|
2006-10-10 |
2012-01-17 |
Rigel Pharmaceuticals, Inc. |
Pinane-substituted pyrimidinediamine derivatives useful as Axl inhibitors
|
JP5406725B2
(ja)
|
2006-12-14 |
2014-02-05 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
タンパク質キナーゼ阻害剤として有用な化合物
|
US7709482B2
(en)
|
2006-12-29 |
2010-05-04 |
Rigel Pharmaceuticals, Inc. |
Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors
|
CA2710046C
(en)
|
2006-12-29 |
2016-02-09 |
Rigel Pharmaceuticals, Inc. |
N3-heteroaryl substituted triazoles and n5-heteroaryl substituted triazoles useful as axl inhibitors
|
WO2008083353A1
(en)
|
2006-12-29 |
2008-07-10 |
Rigel Pharmaceuticals, Inc. |
Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors
|
WO2008098139A2
(en)
|
2007-02-07 |
2008-08-14 |
The Regents Of The University Of Colorado |
Axl tyrosine kinase inhibitors and methods of making and using the same
|
MX2009010556A
(es)
|
2007-03-29 |
2009-10-22 |
Panacea Biotec Ltd |
Formas de dosificacion modificada de tacrolimus.
|
KR101185899B1
(ko)
|
2007-06-12 |
2012-09-27 |
콘서트 파마슈티컬즈, 인크. |
아자펩티드 유도체
|
JP5380447B2
(ja)
|
2007-08-15 |
2014-01-08 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
増殖性疾患の処置のための、ヒトタンパク質キナーゼplk1ないしplk4の阻害剤としての4−(9−(3,3−ジフルオロシクロペンチル)−5,7,7−トリメチル−6−オキソ−6,7,8,9−テトラヒドロ−5h−ピリミド[4,5−b[1,4]ジアゼパン−2−イルアミノ]−3−メトキシベンザミド誘導体
|
GB0719803D0
(en)
|
2007-10-10 |
2007-11-21 |
Cancer Rec Tech Ltd |
Therapeutic compounds and their use
|
JP2011500778A
(ja)
|
2007-10-25 |
2011-01-06 |
アストラゼネカ・アクチエボラーグ |
ピリジン及びピラジン誘導体−083
|
EP2205592B1
(en)
|
2007-10-26 |
2013-05-08 |
Rigel Pharmaceuticals, Inc. |
Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors
|
WO2009085185A1
(en)
|
2007-12-19 |
2009-07-09 |
Amgen Inc. |
Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
|
AR070127A1
(es)
|
2008-01-11 |
2010-03-17 |
Novartis Ag |
Pirrolo - pirimidinas y pirrolo -piridinas
|
US9206130B2
(en)
|
2008-04-16 |
2015-12-08 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Quinoline derivatives as AXL kinase inhibitors
|
TWI539953B
(zh)
|
2008-04-28 |
2016-07-01 |
瑞波若斯治療學公司 |
用於治療乳癌之組成物和方法
|
CN102076690A
(zh)
|
2008-06-23 |
2011-05-25 |
维泰克斯制药公司 |
蛋白激酶抑制剂
|
CA2730251C
(en)
|
2008-07-09 |
2016-08-09 |
Rigel Pharmaceuticals, Inc. |
Bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
|
ES2537480T3
(es)
|
2008-07-09 |
2015-06-08 |
Rigel Pharmaceuticals, Inc. |
Triazoles sustituidos con heteroarilo policíclicos útiles como inhibidores de Axl
|
US20120230991A1
(en)
|
2008-07-29 |
2012-09-13 |
Douglas Kim Graham |
Methods and compounds for enhancing anti-cancer therapy
|
EP2158913A1
(en)
|
2008-08-25 |
2010-03-03 |
Ratiopharm GmbH |
Pharmaceutical composition comprising N-[3-chhloro-4-[(3-fluorophenyl)methoxy]phenyl]6-(5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
|
WO2010025073A1
(en)
|
2008-08-28 |
2010-03-04 |
Takeda Pharmaceutical Company Limited |
Dihydroimidazo [ 1, 5-f] pteridines as polo-like kinase inhibitors
|
EP2376491B1
(en)
|
2008-12-19 |
2015-03-04 |
Cephalon, Inc. |
Pyrrolotriazines as alk and jak2 inhibitors
|
CN102307875A
(zh)
|
2009-02-09 |
2012-01-04 |
苏伯俭股份有限公司 |
吡咯并嘧啶基axl激酶抑制剂
|
EP2424368B1
(en)
|
2009-04-29 |
2014-12-31 |
Locus Pharmaceuticals, Inc. |
Pyrrolotriazine compounds
|
EP2432555B1
(en)
|
2009-05-22 |
2014-04-30 |
Incyte Corporation |
N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
CN104945420A
(zh)
|
2009-06-29 |
2015-09-30 |
因塞特公司 |
作为pi3k抑制剂的嘧啶酮类
|
US9249145B2
(en)
|
2009-09-01 |
2016-02-02 |
Incyte Holdings Corporation |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
MX2012003476A
(es)
|
2009-09-25 |
2012-06-19 |
Vertex Pharma |
Metodos para preparar derivados de pirimidina utiles como inhibidores de proteina cinasa.
|
EP2311809A1
(en)
|
2009-10-16 |
2011-04-20 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Quinolinyloxyphenylsulfonamides
|
US8604217B2
(en)
|
2009-11-12 |
2013-12-10 |
Selvita S.A. |
Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
|
US8680108B2
(en)
|
2009-12-18 |
2014-03-25 |
Incyte Corporation |
Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
|
MX364636B
(es)
|
2010-03-10 |
2019-05-03 |
Incyte Corp |
Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1).
|
JP5752232B2
(ja)
|
2010-03-31 |
2015-07-22 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
プロテインキナーゼ阻害剤としての置換ピロロトリアジン化合物
|
CA2761074A1
(en)
|
2010-05-05 |
2011-11-10 |
Vertex Pharmaceuticals Incorporated |
4 substituted pyrazolopyrimidines useful as pkc-theta inhibitors
|
EP2423208A1
(en)
|
2010-08-28 |
2012-02-29 |
Lead Discovery Center GmbH |
Pharmaceutically active compounds as Axl inhibitors
|
WO2012048129A2
(en)
|
2010-10-08 |
2012-04-12 |
Elan Pharmaceuticals, Inc. |
Inhibitors of polo-like kinase
|
ITRM20100537A1
(it)
|
2010-10-12 |
2012-04-12 |
Consiglio Nazionale Ricerche |
Aptamero inibitore del recettore tirosina chinasi axl per uso in terapia
|
JP5917544B2
(ja)
|
2010-11-19 |
2016-05-18 |
インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation |
Jak阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン
|
AU2011329734B2
(en)
|
2010-11-19 |
2015-05-28 |
Incyte Holdings Corporation |
Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
|
WO2012087881A1
(en)
|
2010-12-20 |
2012-06-28 |
Incyte Corporation |
N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
|
US9133162B2
(en)
|
2011-02-28 |
2015-09-15 |
Sunshine Lake Pharma Co., Ltd. |
Substituted quinoline compounds and methods of use
|
MY161199A
(en)
|
2011-03-23 |
2017-04-14 |
Amgen Inc |
Fused tricyclic dual inhibitors of cdk 4/6 and flt3
|
BR112013025387B1
(pt)
|
2011-04-01 |
2021-07-27 |
University Of Utah Research Foundation |
Compostos análogos substituídos da n-fenilpirimidin-2-amina como inibidores da quinase axl, uso dos ditos compostos para o tratamento de um distúrbio de proliferação celular descontrolada, bem como kit compreendendo ditos compostos
|
AR086913A1
(es)
|
2011-06-14 |
2014-01-29 |
Novartis Ag |
4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
|
KR20140040819A
(ko)
|
2011-06-20 |
2014-04-03 |
인사이트 코포레이션 |
Jak 저해제로서의 아제티디닐 페닐, 피리딜 또는 피라지닐 카르복스아미드 유도체
|
MX2013014315A
(es)
|
2011-07-01 |
2014-01-31 |
Bayer Pharma AG |
Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos.
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為jak抑制劑之環己基氮雜環丁烷衍生物
|
PE20181272A1
(es)
|
2011-09-02 |
2018-08-03 |
Incyte Holdings Corp |
Heterociclilaminas como inhibidores de pi3k
|
KR20140078619A
(ko)
|
2011-09-18 |
2014-06-25 |
유로-셀띠끄 소시에떼 아노님 |
약학적 조성물
|
CN102408411B
(zh)
|
2011-09-19 |
2014-10-22 |
北京康辰药业股份有限公司 |
一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
|
AU2012318896B2
(en)
|
2011-10-03 |
2017-03-02 |
The University Of North Carolina At Chapel Hill |
Pyrrolopyrimidine compounds for the treatment of cancer
|
PL2780338T3
(pl)
|
2011-11-14 |
2017-04-28 |
Ignyta, Inc. |
Pochodne uracylu jako inhibitory kinaz AXL i c-MET
|
US9522892B2
(en)
|
2011-11-29 |
2016-12-20 |
Perosphere Inc. |
Anticoagulant reversal agents
|
WO2013085802A1
(en)
|
2011-12-06 |
2013-06-13 |
Merck Sharp & Dohme Corp. |
Pyrrolopyrimidines as janus kinase inhibitors
|
DK2810937T3
(en)
|
2012-01-31 |
2017-03-13 |
Daiichi Sankyo Co Ltd |
PYRIDONE DERIVATIVES
|
WO2013124316A1
(en)
|
2012-02-23 |
2013-08-29 |
Bayer Intellectual Property Gmbh |
Substituted benzothienyl-pyrrolotriazines and uses thereof
|
WO2013162061A1
(ja)
|
2012-04-26 |
2013-10-31 |
第一三共株式会社 |
二環性ピリミジン化合物
|
TW201406761A
(zh)
|
2012-05-18 |
2014-02-16 |
Incyte Corp |
做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
|
US10227357B2
(en)
|
2012-09-06 |
2019-03-12 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
CN104995192A
(zh)
|
2012-09-26 |
2015-10-21 |
加利福尼亚大学董事会 |
Ire1的调节
|
WO2014062774A1
(en)
|
2012-10-17 |
2014-04-24 |
The University Of North Carolina At Chapel Hill |
Pyrazolopyrimidine compounds for the treatment of cancer
|
SG10201703533VA
(en)
|
2012-11-01 |
2017-06-29 |
Incyte Corp |
Tricyclic fused thiophene derivatives as jak inhibitors
|
CN104936963B
(zh)
|
2012-11-20 |
2017-11-28 |
普罗齐纳斯有限公司 |
作为蛋白激酶抑制剂的硫醚衍生物
|
WO2014109858A1
(en)
|
2013-01-14 |
2014-07-17 |
Amgen Inc. |
Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
|
TW201522337A
(zh)
|
2013-03-12 |
2015-06-16 |
Arqule Inc |
經取代之三環吡唑並-嘧啶化合物類
|
TWI649308B
(zh)
|
2013-07-24 |
2019-02-01 |
小野藥品工業股份有限公司 |
喹啉衍生物
|
EP3067356B1
(en)
|
2013-11-08 |
2018-07-04 |
ONO Pharmaceutical Co., Ltd. |
Pyrrolo pyrimidine derivative
|
JP6162904B2
(ja)
|
2014-02-03 |
2017-07-12 |
カディラ ヘルスケア リミティド |
新規複素環式化合物
|
GB201420285D0
(en)
|
2014-11-14 |
2014-12-31 |
Bergenbio As |
Process
|
WO2016097918A1
(en)
|
2014-12-18 |
2016-06-23 |
Pfizer Inc. |
Pyrimidine and triazine derivatives and their use as axl inhibitors
|
US9840503B2
(en)
|
2015-05-11 |
2017-12-12 |
Incyte Corporation |
Heterocyclic compounds and uses thereof
|
PL3328419T3
(pl)
|
2015-07-30 |
2021-12-27 |
Macrogenics, Inc. |
Cząsteczki wiążące pd-1 i sposoby ich zastosowania
|
WO2017027717A1
(en)
|
2015-08-12 |
2017-02-16 |
Incyte Corporation |
Bicyclic fused pyrimidine compounds as tam inhibitors
|
WO2017035366A1
(en)
|
2015-08-26 |
2017-03-02 |
Incyte Corporation |
Pyrrolopyrimidine derivatives as tam inhibitors
|
US20180296561A1
(en)
|
2015-10-07 |
2018-10-18 |
The University Of North Carolina At Chapel Hill |
The Methods For Treatment Of Tumors
|
CA3000803C
(en)
|
2015-10-13 |
2020-03-24 |
Nihon Nohyaku Co., Ltd. |
Oxime group-containing condensed heterocyclic compound or salt thereof, agricultural and horticultural insecticide comprising the compound, and method for using the insecticide
|
US9695150B2
(en)
|
2015-11-14 |
2017-07-04 |
Calitor Sciences, Llc |
Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
|
US9920033B2
(en)
|
2015-11-14 |
2018-03-20 |
Calitor Sciences, Llc |
Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
|
TWI828027B
(zh)
*
|
2016-03-28 |
2024-01-01 |
美商英塞特公司 |
作為tam抑制劑之吡咯并三嗪化合物
|
CN109414410B
(zh)
*
|
2016-04-22 |
2022-08-12 |
因赛特公司 |
Lsd1抑制剂的制剂
|
WO2017223414A1
(en)
|
2016-06-24 |
2017-12-28 |
Incyte Corporation |
HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
|
RS63928B1
(sr)
|
2016-07-15 |
2023-02-28 |
Ionis Pharmaceuticals Inc |
Jedinjenja i metode za modulaciju smn2
|
JOP20170153A1
(ar)
|
2016-07-15 |
2019-01-30 |
Lilly Co Eli |
نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
|
JOP20190257A1
(ar)
|
2017-04-28 |
2019-10-28 |
Novartis Ag |
مركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 واستخدامها كمثبطات lats
|
KR20200088308A
(ko)
|
2017-09-27 |
2020-07-22 |
인사이트 코포레이션 |
Tam 억제제로서 유용한 피롤로트리아진 유도체의 염
|
WO2020006408A1
(en)
|
2018-06-29 |
2020-01-02 |
Incyte Corporation |
Formulations of an axl/mer inhibitor
|
KR20230017165A
(ko)
|
2020-03-06 |
2023-02-03 |
인사이트 코포레이션 |
Axl/mer 및 pd-1/pd-l1 억제제를 포함하는 병행 요법
|